Clinical significance of elevation in neuroendocrine factors and interleukin-6 in metastatic prostate cancer

Hoosein, Naseema M.; Abdul, Mansoor; McCabe, Richard P.; Gerö, E.; Deftos, Leonard J.; Banks, Marie; Hodges, Sherie; Finn, Laury; Logothetis, Christopher J.

doi:10.1016/1078-1439(96)00012-9

Cited by 45 publications

(39 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although most elevations of serum markers were found in AI tumors, some were not, leading them to theorize a role for NED in the progression of CaP before AD. Their study corroborated findings by Hoosein et al 38 that NED markers correlated more with metastasis than locally advanced disease.…”

Section: Products Action In Cap Referencessupporting

confidence: 81%

Clinical implications of neuroendocrine differentiation in prostate cancer

Nelson

Cambio

Yang

et al. 2006

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

The cellular signaling pathways of the prostate play a central role in the induction, maintenance, and progression of prostate cancer (CaP). Neuroendocrine (NE) cells demonstrate attributes that suggest they are an integral part of these signaling cascades. We summarize what is known regarding NE cells in CaP focusing on NE cellular transdifferentiation. This significant event in CaP progression appears to be accelerated by androgen deprivation (AD) treatment. We examine biochemical pathways that may impact NE differentiation in a chronological manner focusing on AD therapy (ADT) as a central event in inducing androgen-independent CaP. Our analysis is limited to the common adenocarcinoma pattern of CaP and excludes small-cell and carcinoid prostatic variants. In conclusion, we speculate on the future of treatment and research in this area.

show abstract

Section: Products Action In Cap Referencessupporting

confidence: 81%

Clinical implications of neuroendocrine differentiation in prostate cancer

Nelson

Cambio

Yang

et al. 2006

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

show abstract

“…Among 135 patients with prostate cancer, Cussenot and coworkers (1996) detected increased serum concentrations of chromogranin A and NSE in 23 (17%) and 20 (15%), respectively, before any endocrine treatment, and they speculated that neuroendocrine products may be involved in the progression of prostate cancer independently of androgen withdrawal. However, increased serum concentrations of chromogranin A were more consistently found in patients with androgen-insensitive tumours (Cussenot et al 1996), in agreement with a report by Hoosein et al (1995). Both studies showed a correlation between neuroendocrine serum markers and distant metastases, but not between serum markers and locally progressive disease (Hoosein et al 1995, Cussenot et al 1996.…”

Section: Serum Markerssupporting

confidence: 77%

“…However, increased serum concentrations of chromogranin A were more consistently found in patients with androgen-insensitive tumours (Cussenot et al 1996), in agreement with a report by Hoosein et al (1995). Both studies showed a correlation between neuroendocrine serum markers and distant metastases, but not between serum markers and locally progressive disease (Hoosein et al 1995, Cussenot et al 1996. In a recent study, the number of chromogranin Apositive neuroendocrine tumour cells was found to be correlated with the serum chromogranin A concentration (Angelsen et al 1997a), supporting the results of an earlier study .…”

Section: Serum Markerssupporting

confidence: 77%

Neuroendocrine cells in tumour growth of the prostate.

Abrahamsson¹

1999

Endocrine-Related Cancer

228

198

View full text Add to dashboard Cite

The prognostic significance of neuroendocrine differentiation in prostatic malignancy is controversial, but the results of recent studies with markers such as chromogranin A and neurone-specific enolase suggest that neuroendocrine differentiation, as reflected by increased tissue expression or blood concentrations of these neuroendocrine secretory products, is associated with a poor prognosis, tumour progression, and androgen independence. As all malignant neuroendocrine cells are devoid of androgen receptors and the expression of neuroendocrine cells is not suppressed by androgen ablation, clonal propagation of androgen receptor-negative neuroendocrine cells may have an important role in the development of androgen-independent prostatic carcinoma. This has significant implications for the treatment of prostate cancer, because several of the hormones that are secreted by neuroendocrine differentiated, malignant prostatic cells are potential candidates for use in drug treatment. A limited number of hormones have been tested in this context, in particular somatostatin, bombesin, and serotonin. As there is currently no successful treatment for differentiated prostate cancer, new therapeutic procedures and trials need to be developed to test drugs based on Endocrine-Related Cancer (1999) 6 503-519 neuroendocrine hormones or their antagonists.

show abstract

“…(22 )]. IL-6 is also increased in the sera of patients with metastatic prostate cancer (23)(24)(25) and hormone-refractory disease (26 ), and may be a surrogate marker for androgen-independent disease. Other potential markers of prostate cancer currently being investigated include cadherin (27 ), human kallikrein 2 (28 ), and chromogranin A (29 ).…”

mentioning

confidence: 99%

Identification of Serum Amyloid A as a Biomarker to Distinguish Prostate Cancer Patients with Bone Lesions

Tyldesley

et al. 2005

Clinical Chemistry

103

View full text Add to dashboard Cite

Background: Prostate cancer has a propensity to metastasize to the bone. Currently, there are no curative treatments for this stage of the disease. Sensitive biomarkers that can be monitored in the blood to indicate the presence or development of bone metastases and/or response to therapies are lacking. Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) is an affinity-based approach that allows sensitive and high-throughput protein profiling and screening of biological samples. Methods: We used SELDI-TOF MS for protein profiling of sera from prostate cancer patients (n ‫؍‬ 38) with and without bone metastases in our effort to identify individual or multiple serum markers that may be of added benefit to those in current use. Serum was applied to ProteinChip ® surfaces (H4 and IMAC) to quickly screen samples and detect peaks predominating in the samples obtained from patients with bone metastases. Unique proteins in the bone metastasis cohort observed by SELDI-TOF MS were identified by two-dimensional gel electrophoresis, in-gel trypsin digestion, and tandem MS. The identities of the proteins were confirmed by ELISA and immunodepletion assays. Results: The cluster of unique proteins in the sera of patients with bone metastases was identified as isoforms of serum amyloid A. Machine-learning algorithms were also used to identify patients with bone metastases with a sensitivity and specificity of 89.5%.

show abstract

Clinical significance of elevation in neuroendocrine factors and interleukin-6 in metastatic prostate cancer

Cited by 45 publications

References 20 publications

Clinical implications of neuroendocrine differentiation in prostate cancer

Clinical implications of neuroendocrine differentiation in prostate cancer

Neuroendocrine cells in tumour growth of the prostate.

Identification of Serum Amyloid A as a Biomarker to Distinguish Prostate Cancer Patients with Bone Lesions

Contact Info

Product

Resources

About